Pharming convenes Extraordinary General Meeting of shareholders
Financial updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting (EGM) of Shareholders on Friday 11 December 2020 at 14:00 CET.
Pharming Group reports financial results for the first nine months of 2020
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the nine months and third quarter ended 30 September 2020.
Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
Operational updatesPharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).
Sign up now: Pharming’s Q3 Webinar
WebinarsOn the 29th of October at 19:00 Pharming’s CEO, Sijmen de Vries will discuss the recently published Q3 2020 financial results, provide a business update and insight into market developments. Submit your questions in advance to investor@pharming.com
Pharming announces the publication of data from a compassionate use program of RUCONEST® in COVID-19 patients in a peer-reviewed journal
Clinical trialsPharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use program of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.
Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®
Clinical trialsPharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.
Pharming Group reports financial results for the first half of 2020
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020.
Sign up now! Pharming Webinar: Half year results
WebinarsPharming’s CEO Sijmen de Vries and Leon Melens look back at the first half year and the recently published half year financial results.
Pharming Reports on Annual General Meeting of Shareholders
Financial updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, the proposals related to remuneration were withdrawn and all other proposals were approved.
Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors
Operational updatesPharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.